Insider Transactions in Q1 2024 at Ptc Therapeutics, Inc. (PTCT)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+14.1%
|
-
|
|
Feb 15
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
870
+15.98%
|
-
|
|
Feb 15
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+12.83%
|
-
|
|
Feb 15
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
16,900
+13.64%
|
-
|
|
Feb 15
2024
|
Michael Schmertzler |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+6.09%
|
-
|
|
Feb 15
2024
|
David P Southwell |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.62%
|
-
|
|
Feb 15
2024
|
William F. Bell Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+27.91%
|
-
|
|
Feb 15
2024
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+28.85%
|
-
|
|
Feb 15
2024
|
Mary L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+22.46%
|
-
|
|
Feb 15
2024
|
Glenn Jr Md Phd Steele |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.62%
|
-
|
|
Feb 15
2024
|
Alethia Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+23.44%
|
-
|
|
Feb 15
2024
|
Jerome B Zeldis |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.62%
|
-
|
|
Feb 15
2024
|
Allan Steven Jacobson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+19.66%
|
-
|
|
Feb 15
2024
|
Emma Reeve |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+26.32%
|
-
|
|
Feb 15
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Grant, award, or other acquisition
|
Direct |
21,200
+10.07%
|
-
|
|
Feb 15
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+23.3%
|
-
|
|
Feb 15
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,600
+14.89%
|
-
|
|
Feb 15
2024
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,100
+15.88%
|
-
|
|
Jan 30
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
318
-0.89%
|
$8,586
$27.25 P/Share
|
|
Jan 30
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
366
-0.82%
|
$9,882
$27.25 P/Share
|
|
Jan 30
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
794
-1.1%
|
$21,438
$27.25 P/Share
|
|
Jan 30
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
28
-0.75%
|
$756
$27.25 P/Share
|
|
Jan 30
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
618
-1.0%
|
$16,686
$27.25 P/Share
|
|
Jan 22
2024
|
Allan Steven Jacobson |
SELL
Open market or private sale
|
Direct |
10,000
-44.75%
|
$270,000
$27.38 P/Share
|
|
Jan 22
2024
|
Allan Steven Jacobson |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.91%
|
$270,000
$27.05 P/Share
|
|
Jan 09
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,653
-4.41%
|
$47,937
$29.01 P/Share
|
|
Jan 09
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,938
-2.62%
|
$56,202
$29.01 P/Share
|
|
Jan 09
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,225
-3.13%
|
$35,525
$29.01 P/Share
|
|
Jan 09
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,443
-3.28%
|
$157,847
$29.01 P/Share
|
|
Jan 09
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,065
-4.43%
|
$59,885
$29.01 P/Share
|
|
Jan 09
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
100
-2.61%
|
$2,900
$29.01 P/Share
|
|
Jan 09
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,521
-2.4%
|
$44,109
$29.01 P/Share
|
|
Jan 08
2024
|
Michael Schmertzler |
SELL
Open market or private sale
|
Direct |
1,500
-1.28%
|
$40,500
$27.81 P/Share
|
|
Jan 08
2024
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,188
-3.07%
|
$33,264
$28.64 P/Share
|
|
Jan 08
2024
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,457
-1.93%
|
$40,796
$28.64 P/Share
|
|
Jan 08
2024
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
775
-1.94%
|
$21,700
$28.64 P/Share
|
|
Jan 08
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,237
-1.33%
|
$62,636
$28.64 P/Share
|
|
Jan 08
2024
|
Eric Pauwels CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,569
-3.26%
|
$43,932
$28.64 P/Share
|
|
Jan 08
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
53
-1.36%
|
$1,484
$28.64 P/Share
|
|
Jan 08
2024
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,236
-1.91%
|
$34,608
$28.64 P/Share
|
|
Jan 05
2024
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,107
-5.67%
|
$272,889
$27.15 P/Share
|